CEO sold ~$1.77M of Gilead Sciences
Scheduled in advanceLoading…
GILD · NASDAQ · Biotechnology
Biotechnology company based in Foster City, California.
Last close, Oct 1, 2026
$147.50
Adjusted for splits and dividends
Last 12 months
+32.7%
S&P 500 +14.3% over the same dates
Market value
$183B
Last close × shares outstanding
Bets against the stock: 18.3M shares sold short (1.5% of shares outstanding), -20.4% vs the previous count, 3.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
26 sales
$15.7M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$29.4B
+2.4% vs the year before
Net income, fiscal 2025
$8.51B
As reported in the annual filing
Shares outstanding
1.24B
As of Jul 31, 2026
In fiscal 2025 the company spent $1.92B buying back its own shares and $4B on dividends. Cash actually paid, from its cash-flow statement.
CEO sold ~$1.77M of Gilead Sciences
Scheduled in advanceCEO sold ~$446K of Gilead Sciences
Scheduled in advanceCFO sold ~$436K of Gilead Sciences
Scheduled in advanceOfficer sold ~$116K of Gilead Sciences
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 42.5% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 41.5%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
7 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last 12 months, adjusted daily closes
Adjusted close went from $111.15 on Oct 1, 2025 to $147.50 on Oct 1, 2026 (+32.7%). Disclosed trades in the last 12 months: 0 insider purchases, 79 insider sales (78 under pre-arranged plans), 4 Congress purchases, 0 Congress sales.
6 notices filed with state agencies, covering 287 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
83 certified in FY2026 Q3, vs 51 a year earlier. 83 positions in total, median offered wage $159K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.